BYBin Yang

Bin Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bin Yang has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An interpretable machine learning tool for rheumatoid arthritis screening: integrating novel cellular morphological parameters with routine blood count indices

    by Lan You, Xin Li, Ruocheng Luo, Chen Peng, Qianhui Liu, Ruichun Sun, Nan Zhang, Jie Hou, Bin Yang

    Background Rheumatoid arthritis (RA) is a chronic autoimmune disease that can cause significant disability. Early detection is vital for improving outcomes, but current diagnostic methods are costly and lack accessibility for wide-scale screening. While routine blood cell parameters are promising, novel cellular morphological indices (e.g., NE-SFL, LY-Y) remain under-explored for RA screening. This study aimed to develop a machine learning model for RA screening by integrating novel morphological with routine blood parameters. Methods This retrospective study analyzed 43 blood cell parameters from 3009 participants. Feature selection used multiple machine learning (ML) algorithms, and eight predictive models were developed. Performance was evaluated on an independent test set via AUC, accuracy, sensitivity, specificity, calibration, and decision curve analysis. Model interpretability was provided by SHapley Additive exPlanations (SHAP). Results Seven key predictors were identified. The XGBoost model performed best, achieving an AUC of 0.929, accuracy of 0.890, sensitivity of 0.774, and specificity of 0.915 on the test set. SHAP analysis showed that novel cellular morphological parameters were the primary predictive drivers, exceeding some traditional inflammatory markers. Conclusion We developed and validated a high-performance, interpretable ML model using blood parameters to identify individuals at high risk for RA. The results highlight the significant value of novel morphological parameters for RA screening. An accompanying online tool offers a feasible, low-cost solution for non-invasive RA screening in primary care settings. Key Points •Focus on RA screening: The model is designed specifically for screening and risk stratification of RA where timely intervention is most critical. •High performance with routine data: Using only seven readily available blood parameters, our XGBoost model achieved an AUC of 0.929 on an independent test set, demonstrating performance comparable to more complex or costly modalities •Translational readiness: We have operationalized this model into a freely accessible online tool, enabling immediate clinical use. This tool can serve as an efficient “pre-screening filter” in routine health checks, guiding the referral of high-risk individuals for specialist evaluation and confirmatory testing (e.g., anti-CCP, imaging). •Interpretability for clinical trust: We employed SHAP analysis to ensure model transparency, explaining both global feature importance and individual predictions. This interpretability is crucial for fostering clinician adoption and understanding the biological underpinnings of the predictions, such as the prominent role of cellular morphological parameters like LY-Y and NE-SFL.

  • Evaluating the performance of four anti-dsDNA antibody detection methods

    by Xuedan Gao, Liqiong Wu, Yi Li, Li Wang, Zhuochun Huang, Junlong Zhang, Zhenzhen Su, Bin Yang

    Objective: To evaluate the concordance of four anti-dsDNA antibody detection methods—Crithidia luciliae indirect immunofluorescence test (CLIFT), enzyme-linked immunosorbent assay (ELISA), acridine ester direct chemiluminescence immunoassay (CLIA), and digital liquid chip method (DLCM)—and to assess their diagnostic efficacy in systemic lupus erythematosus (SLE) patients. Methods: A total of 285 serum samples were collected, including 170 SLE patients, 39 with non-SLE autoimmune diseases (AIDs), 28 with non-AIDs, and 48 undiagnosed cases. The concordance and diagnostic performance of anti-dsDNA antibody methods were analyzed. Results: The diagnostic performance showed that DLCM exhibited the highest sensitivity (86.87%), while CLIA demonstrated the highest specificity (94.03%). The area under the receiver operating characteristic (ROC) curve (AUC) was ranked as CLIFT < ELISA < CLIA < DLCM (AUC = 0.938). Anti-dsDNA antibodies detected by both CLIFT and DLCM correlated well with the SLE disease activity index (SLEDAI), while CLIFT and CLIA were significantly correlated with lupus nephritis. Utilizing ROC curve-derived cut-off values, the overall concordance of CLIFT and other methods ranged from 80.14% to 82.58% (kappa > 0.6, P < 0.001), and the concordance between quantitative methods ranged from 89.55% to 91.29% (kappa > 0.8, P < 0.001). Conclusion: CLIFT, ELISA, CLIA, and DLCM all showed impressive diagnostic efficacy in detecting anti-dsDNA antibodies. CLIFT shows a strong correlation with SLE activity and lupus nephritis. DLCM, a relatively new method, also showed excellent performance and could be integrated into clinical laboratory workflows for anti-dsDNA antibody testing.


  • CircRNA_0001412 and CircRNA_0001566 as Potential Biomarkers for the Diagnosis of Rheumatoid Arthritis

    by Xin Li, Ao Deng, Zehao Wang, Shenling Liao, Kaihong Luo, Jing Hu, Bin Yang

    Rheumatoid arthritis (RA) is a chronic autoimmune disease with high disability rates, necessitating early diagnosis. This study investigated the potential of circRNAs, specifically CircRNA_0001412 and CircRNA_0001566, as diagnostic biomarkers for RA. High-throughput transcriptome sequencing was performed on peripheral blood mononuclear cells (PBMCs) from RA patients and healthy controls to identify differentially expressed circRNAs. Reverse transcription quantitative PCR (RT-qPCR) was used to validate circRNA expression in an independent cohort of 78 RA patients and 82 healthy controls. Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic value of the selected circRNAs. Correlation analyses with clinical markers such as CRP, ESR, CCP, RF, WBC, lymphocyte count, and monocyte count were also conducted. Bioinformatics analyses, including GO and KEGG pathway enrichment, were conducted to explore the functional roles of the identified circRNAs and associated miRNAs. A total of 54 circRNAs were identified as differentially expressed in RA, with 21 circRNAs upregulated and 33 downregulated. Among these, CircRNA_0001412 and CircRNA_0001566 were highly expressed in RA PBMCs and demonstrated good sensitivity and specificity as diagnostic biomarkers (AUC = 0.751 (95%CI 0.673, 0.830) and 0.605(95%CI 0.516, 0.694)). Combined analysis of these circRNAs further improved diagnostic performance (AUC = 0.776 (95%CI 0.702, 0.851)). Notably, CircRNA_0001412 showed a significant correlation with CRP, suggesting its potential as a biomarker for RA disease severity. Bioinformatics analysis predicted that CircRNA_0001412 and CircRNA_0001566 could promote T-cell activation via the PI3K-Akt signaling pathway, contributing to RA pathogenesis. CircRNA_0001412 and CircRNA_0001566 are promising diagnostic biomarkers for RA, with CircRNA_0001412 additionally serving as a potential indicator of inflammatory activity. These findings provide a basis for further research into the diagnostic and prognostic utility of circRNAs in RA.


  • Open Access

    A Longitudinal Study Reveals Metabolomic Markers for Individuals at Risk, Disease Severity, and Treatment Response in Rheumatoid Arthritis

    by Chenxi Zhu, Jiayi Xu, Siyu He, Qian Niu, Yi Liu, Xin Guo, Huifang Hu, Rui Sun, Tao Chen, Yan Liu, et al.

    Rheumatoid arthritis (RA) is a systemic inflammatory joint disease characterized by heterogeneous clinical manifestations, which requires deeper exploration in identifying reliable biomarkers for early diagnosis, monitoring, and treatment assessment. The aim is to discover plasma metabolomic markers to predict RA onset, assess disease activity, and forecast treatment efficacy. The study includes 209 established RA patients who are disease‐modifying antirheumatic drugs‐free for six months prior to enrollment, with 197 of them followed for 3–6 months to assess treatment response. Additionally, 56 individuals at risk are recruited, with 34 completing a 5–7‐year follow‐up. Analysis reveals that metabolites related to methylation and redox imbalance, such as S‐adenosylmethionine, sarcosine, nicotinamide adenine dinucleotide, glutathione, etc., are associated with RA development and severity, and contribute to its heterogeneity across age, sex, and anti‐citrullinated protein autoantibody status. Ridge regression models are constructed using metabolite and clinical features for the response to methotrexate (MTX) plus leflunomide, achieving an average receiver operating characteristic (ROC) score of 0.83, and for the MTX plus hydroxychloroquine, achieving an average ROC score of 0.92. In conclusion, our findings reveal RA metabolomic alterations, aiding early diagnosis and treatment response.


  • Open Access

    Remodeling of T-cell mitochondrial metabolism to treat autoimmune diseases

    by Liyan Lin, Ruyu Ren, Qiao Xiong, Chunfu Zheng, Bin Yang, Huiqing Wang


  • Blood and CSF findings of cellular immunity in anti-NMDAR encephalitis

    by Jierui Wang, Limei Luo, Zirui Meng, Yan Ren, Meng Tang, Zhuochun Huang, Bin Yang, Qian Niu, Dong Zhou, Minjin Wang, et al.


  • Gene polymorphisms of an interleukin‐23 receptor associated with susceptibility to rheumatoid arthritis in the Western Chinese Han population

    by Ruyu Ren, Huiling Tan, Xuean Wang, Li Wang, Bin Yang

    Rheumatoid arthritis (RA) is a chronic inflammatory disease which is closely related to genetic background. Single‐nucleotide polymorphisms (SNPs) have been found to play an important role in the development of RA. This study intends to investigate the links between gene polymorphisms in the interleukin‐23 receptor (IL23R) and interleukin 17A (IL17A) and susceptibility to RA in the Western Chinese Han population. Four SNPs (rs6693831 T > C, rs1884444 G > T, and rs7517847 T > G in IL23R gene, and rs2275913 G > A in IL17A gene) were genotyped in 246 RA patients and 362 healthy controls by high resolution melting analysis. The comparative analyses among genotype distributions, clinical indicators, and IL‐17A and IL‐23R levels in RA patients were also performed. The study revealed that the SNP rs6693831 and rs1884444 of IL23R had a significant association with RA susceptibility. The frequencies of rs6693831 genotype CC and allele C were significantly higher in the RA group and associated with higher RA risk compared with genotype TT and allele T (OR = 7.797, 95% confidence interval [CI] = 4.072–14.932 and OR = 5.984, 95%CI = 3.190–11.224, respectively). The TT genotype of rs1884444 appeared to decrease the RA risk compared with the GG genotype (OR = .251, 95%CI = .118–.536). The genotype CC and allele C of rs6693831 and the genotype GG and allele G of rs1884444 may be risk factors for RA. IL23R gene polymorphisms may be involved in the risk of RA susceptibility in the Western Chinese Han population.


  • Open Access

    Clinical Performance of the Line Immunoassay, Digital Liquid Chip Method, and Chemiluminescent Immunoassay for Detecting Specific Antinuclear Antibodies

    by Zhenzhen Su, Li Wang, Xuedan Gao, Zhuochun Huang, Jing Hu, Bin Yang

    Context: Antinuclear antibodies (ANAs) against certain antigens are useful for identifying autoimmune disorders. Although new solid phase–based immunoassays have been developed for evaluating ANAs, the conventional line immunoassay (LIA) is commonly used in clinical practice. Objective: To compare the clinical performance of 2 newly developed methods for detecting specific ANAs with LIA. Design: Six hundred ninety-six serum samples were collected from 559 patients with autoimmune disease (AID) and 137 controls. The samples were screened by using the LIA, digital liquid chip method (DLCM), and chemiluminescent immunoassay (CLIA) for specific ANAs. The agreement across assays and the clinical performance of each assay in diagnosing ANA-associated rheumatic diseases (AARDs) were evaluated. Results: Almost perfect agreement was observed among all assays for anti–centromere protein B (κ = 0.85–0.97), anti–ribosome P (κ = 0.85–0.88), anti–SSA 52 (κ = 0.86–0.89), and anti–SSA 60 (κ = 0.89–0.91); moderate to substantial agreement was detected for the autoantibodies against Sm, Jo-1, ribonucleoprotein, Scl-70, and SSB (κ = 0.55–0.80). LIA exhibited better sensitivity for diagnosing AARDs, while DLCM and CLIA demonstrated higher specificity. In the subset of AIDs, especially systemic lupus erythematosus, antibody positive percentages varied greatly between assays. Conclusions: The 3 assays showed comparable qualitative agreement; however, the standardization of testing for ANAs remains challenging owing to intermanufacturer variations. Moreover, DLCM and CLIA exhibited better specificity in distinguishing non-AID individuals, whereas LIA was more sensitive in diagnosing AARDs.